Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs).

SPEAKER: In the last few decades, doctors have made significant progress treating RA. That's mostly due to two types of prescriptions, disease-modifying antirheumatic drugs or DMARDs and biologics.

Established RA is usually stage 2. Advanced RA might correspond to stage 3 or stage 4. Disease-modifying antirheumatic drugs ...

Patients with rheumatoid arthritis who use biological DMARDs are unlikely to achieve sustained DMARD-free remission.

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in RA.

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects ∼0.8% of the adult population worldwide. Onset typically occurs between 30 and 50 years of age, with an ...

Leflunomide is the only nonbiologic DMARD developed specifically for the treatment of RA. It is an isoxazole derivative and its active metabolite, teriflunomide (formerly known as A77 1726), acts ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

There are several effective treatments for RA, including DMARDs and biologics. Both types of medications control rheumatoid arthritis by lowering the inflammation that fuels it, but there are ...

Aggressive early use of DMARDs is indicated for patients with RA to prevent joint damage and improve physical function as well as health-related quality of life. Targeting patient outcomes with ...